The immunosuppressive drug cyclosporin A has been shown to be effective in preventing corneal allograft reactions in rabbits when administered by intramuscular injection. However, when used systemically in man, the drug may have potentially serious side effects and a series ofexperiments has therefore been performed in order to investigate the use of topically applied cyclosporin A in rabbit corneal transplants. Using a single set model of the corneal allograft reaction, two groups of rabbits treated with topically applied cyclosporin A for periods of four and thirteen weeks respectively showed significantly increased graft survival compared with untreated controls (P < 0.001).
Introduction
Cyclosporin A is a cyclic polypeptide containing II amino acids which can be extracted from the fungus Trichoderma polysporum. It is a powerful immunosuppressive agent which has been shown in vitro to inhibit proliferation of previously stimulated mouse T but not B lymphocytes. Because of its preferential action on T lymphocytes, cyclosporin A has been the subject of much investigation in the field of transplant surgery and the results of both animal experiments and clinical trials have been encouraging (Lancet 1979) . Among many animal studies, renal allografts in rabbits (Green et al. 1979) , heart transplants in pigs (Caine et al. 1978) ,bone marrow grafts in rats (Tutschka et al. 1979) and corneal grafts in rabbits (Shepherd et al. 1980 ) have all shown prolonged survival when treated with either oral or intramuscular cyclosporin A. In some instances the period of survival continued for II months following withdrawal of the drug, suggesting a form of continued tolerance to the grafted tissue (Green et al. 1979 , Caine et al. 1978 . In man no such tolerance has been observed but, nevertheless, clinical trials have yielded promising results in patients who were maintained on the drug. A recent renal transplant series produced an 86% survival at one year . Trials are also being carried out in pancreatic, liver, heart and bone marrow transplant programmes.
A number of side effects in man have been observed, the most serious being an increased incidence of lymphoma and nephrotoxicity in those patients maintained on systemic cyclosporin A for renal and other transplants (Lancet 1979) .The cases of lymphoma occurred in patients who were receiving additional immunosuppressants and may have been related to excessive immunosuppression. The renal toxicity, however, has occurred in patients receiving cyclosporin A alone (Hamilton et al. 1981) and has sometimes necessitated withdrawal of the drug to protect renal function from further damage. The systemic use of a drug with such side effects cannot be justified for non-essential organ transplantation such as corneal grafting, even though it has been shown to be effective in preventing corneal graft rejection in rabbits.
It may, however, not be necessary to administer cyclosporin A systemically to interfere with corneal graft rejection, for local rather than systemic immune mechanisms may have a predominant role in initiating or potentiating graft rejection (Jones 1973) . If this proved to be the case, the use of topically applied cyclosporin A (without the attendant risks of systemic exposure to the drug) might prove effective in preventing corneal graft rejection. In order to test this hypothesis a series of experiments has been performed using rabbit models of corneal graft rejection and topically applied cyclosporin A. 
Methods
The first rabbit model used was the same as that used to test the effects of systemically administered cyclosporin A and these results have already been described elsewhere (Shepherd et al. 1980) . This is a well established model which relies on skin transfer to ensure sensitization and the reaction in the cornea is therefore a second set reaction. Topically administered cyclosporin A had no effect on corneal graft rejection in this model but this was to be anticipated. A new model was therefore needed in which corneal graft rejection could be initiated consistently through corneal transfer only, and this was achieved by exchanging paired corneal grafts taken from rabbits of different breeds and placing the corneal grafts peripherally. This has the effect of ensuring iris adhesions, and maximal vascularization.
The recipient eye was treated with topical antibiotic ointment and mydriatics until the removal of the continuous 10/0 nylon suture on the fourteenth postoperative day. Rejection was readily diagnosed by the appearance of epithelial (Figure I A) or endothelial rejection lines, or the appearance of clouding in a previously clear graft stroma. Cyclosporin A drops were administered to the recipient eye as a I%solution dissolved in arachis oil.
Results
In a series of untreated corneal allografts, the onset of rejection occurred' between the 14th and 34th day postoperatively and the mean survival time was 22 days. When the procedure was repeated using autografted material (with the corneal discs sutured back into the same animal) these grafts remained clear for periods in excess of three months (Figure 2) .
A group of rabbit corneal allografts was then treated with topically applied cyclosporin A 1%in arachis oil five times daily for 28 days following surgery. None of these grafts rejected whilst treatment was maintained. The first day on which any graft rejected was day 31 and one graft remained clear for a period of 77 days. The mean survival time of grafts in this group was 47.3 ± s.d. 12.36 days, which was significantly (P < 0.001) longer than that of a control group which had been treated with arachis oil alone on a fully coded basis (Figure 3) .
Thus it appears that topically applied cyclosporin A is able to inhibit, but not prevent, corneal allograft rejection in rabbits. A further experiment was therefore performed in which treatment was maintained for a period of three months following surgery. After one month the frequency of drops was reduced to twice daily and during the third month each rabbit received only one drop a day to the grafted eye. In this experiment no grafts rejected during the first two months ( Figure IB) but two grafts rejected two to three weeks after the dosage was reduced from twice to once daily (Figure 3) . This time interval is consistent with the build- up of an immune reaction during the period of minimal dosage. After stopping treatment three of the remaining seven grafts rejected, but four grafts have so far stayed clear for 180 days. It is not yet clear whether this prolonged survival represents true immunological tolerance as has been suggested by other workers, or whether it is related simply to regression of corneal vessels.
Discussion
The serious side effects of cyclosporin A when administered systemically would make its use by oral or intramuscular routes hard to justify in clinical corneal grafting. Long-term steroid preparations at present represent the only available topical means of combating graft rejection, but these carry with them the local risks of inducing glaucoma or cataracts (Donshik et al. 1979 ). However, the ability of cyclosporin A when applied topically to inhibit corneal graft rejection in rabbits may represent an alternative form of topical immunosuppression (Hunter et al. 1981 ). Further information is required concerning the ocular pharmacology and toxicity of topically applied cyclosporin A before clinical trials can be started. It is to be hoped, however, that cyclosporin A will prove to be a safe and effective drug in the control of corneal graft rejection, which remains one of the main limitations of successful corneal grafting today.
